Inclusion Criteria:

- Histologically diagnosed malignant solid tumor, including tumors of the CNS, that has
progressed despite standard therapy or for which no effective standard therapy is
known

- Patients with brainstem glioma or intrinsic pontine glioma do not need biopsy
proof of the diagnosis if imaging studies are consistent with the diagnosis

- Measurable or nonmeasurable disease

- No pleural effusion or ascites causing respiratory compromise (≥ grade 2 dyspnea)

- ECOG performance status (PS) 0-2 for patients ≥ 16 years of age

- Karnofsky PS ≥ 40% for patients > 10 years of age

- Lansky Play Scale ≥ 40% for patients ≤ 10 years of age

- Peripheral absolute neutrophil count (ANC) ≥ 1,000/mm^3

- Platelet count ≥ 75,000/mm^3 (transfusion independent)

- Hemoglobin ≥ 8.5 g/dL (transfusion permitted)

- Serum creatinine ≤ 1.5 times upper limit of normal (ULN)

- Creatinine clearance OR radioisotope glomerular filtration rate > 60mL/min

- Total bilirubin < 1.5 mg/dL

- ALT and AST ≤ 2.5 times ULN (5 times ULN if liver involvement with primary tumor)

- Ejection fraction ≥ 50% OR shortening fraction ≥ 28%

- Life expectancy of > 8 weeks

- No radiological evidence of pulmonary fibrosis, interstitial pneumonia, or extensive
and symptomatic interstitial fibrosis of the lung

- Room air oxygen saturation ≥ 90% at altitudes ≥ 5,000 feet OR ≥ 93% at altitudes
< 5,000 feet

- DLCO > 50% of predicted (for patients who received prior bleomycin and are able
to comply with pulmonary function testing)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to platinum or oxaliplatin as well as other agents used in study
treatment

- No other serious or poorly controlled social circumstance, psychiatric illness, or
medical condition including, but not limited to, the following: ongoing or active
infection, uncontrolled seizure disorder, uncontrolled symptomatic congestive heart
failure, or cardiac arrhythmia that could be exacerbated by or complicate compliance
with study therapy

- No HIV-positive patients

- Recovered from prior therapy

- No persistent toxicities from previous therapies ≥ grade 2

- Stable grade 3 neurotoxicity is allowed in patients with CNS tumors only
who have a baseline neurotoxicity due to primary tumor involvement or
postoperative complications

- At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)

- At least 4 weeks since prior local radiotherapy (small port)

- At least 6 months since prior craniospinal irradiation, irradiation to ≥ 50% of the
pelvis, or other substantial bone marrow irradiation, including total body
irradiation

- No previous treatment with oxaliplatin

- At least 14 days since prior biological therapy (including monoclonalantibody
therapy)

- At least 7 days since prior retinoids, sargramostim (GM-CSF), or filgrastim (G-CSF)

- At least 14 days since prior pegfilgrastim

- No concurrent pegfilgrastim or GM-CSF

- Patients requiring steroids should be on stable or decreasing dose for ≥ 7 days prior
to study entry, and must not be on more than 4 mg of dexamethasone (or equivalent)
per day

- At least 4 weeks since prior major surgical procedure

- Simple surgical procedures, including biopsy or central line placement or
similar procedure, are allowed within 4 weeks of study entry if the patient has
recovered to baseline

- At least 3 months since prior autologous or allogeneic stem cell transplantation

- No concurrent immunosuppressive therapy

- No evidence of ongoing graft versus host disease (GVHD)

- No concurrent use of other investigational agents

- No other concurrent anticancer therapies or agents

- No other concurrent chemotherapy, radiation therapy, or herbal medications or
supplements